Standstill period

BankFinancial Corporation Announces Expansion of Board of Directors and Standstill Agreement with Strategic Value Bank Partners, LLC, Strategic Value Investors LP and Benjamin Mackovak

Retrieved on: 
Friday, February 9, 2024
Partner, Standstill agreement, Corporate governance, Annual report, Crowe, Standstill period, Committee, Treasury, Risk

Mr. O’Connor has served on the board of directors of BankFinancial NA since January, 2023.

Key Points: 
  • Mr. O’Connor has served on the board of directors of BankFinancial NA since January, 2023.
  • Mr. O’Connor will serve as a director of BankFinancial Corporation in the class of directors with terms expiring at BFIN’s 2025 Annual Meeting of stockholders.
  • Prior to co-founding Strategic Value Bank Partners, Mr. Mackovak had senior leadership roles and experience with several investment analysis and advisory firms since 2004.
  • On February 7, 2024, BankFinancial Corporation, Strategic Value Bank Partners, LLC, Strategic Value Investors LP and Mr. Mackovak (collectively, the “SVB Partners Parties”) agreed to a Standstill Agreement.

VEON issues amended Scheme

Retrieved on: 
Wednesday, January 11, 2023
United Kingdom, Euronext Amsterdam, Put, Personal Information Agent, Deed, Trustee, Information, Deed poll, Union, Element, Standstill period, Intermediary, Eligibility, Chair, DTC, VEON, Moelis & Company, Republic, Section 4, Appendix, Part, NSD, PJSC VimpelCom, Belarus, Creditor, Explanation, LLP, Note, Russia, United Nations, USD, Exercise, Bermuda, First Nations in Ontario, PJSC, Calendar, Constitutional amendment, Court, Cryptocurrency, Audit, Security (finance), Proxy, Scheme

Amsterdam, Netherlands, 11 January 2023 23:50 CET: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON) (“VEON” or, together with its subsidiaries, the “Group”), a global digital operator that provides converged connectivity and online services, and its subsidiary VEON Holdings B.V. (the “Company”) refer to the announcement dated 21 December 2022 relating to the Company’s proposed scheme of arrangement (the “Scheme”) in respect of the 5.95% notes due February 2023 and 7.25% notes due April 2023 issued by the Company (together, the “2023 Notes”), and in particular relating to the convening of a single meeting of Scheme Creditors to be held on 24 January 2023 (the “Scheme Meeting”).

Key Points: 
  • Amsterdam, Netherlands, 11 January 2023 23:50 CET: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON) (“VEON” or, together with its subsidiaries, the “Group”), a global digital operator that provides converged connectivity and online services, and its subsidiary VEON Holdings B.V. (the “Company”) refer to the announcement dated 21 December 2022 relating to the Company’s proposed scheme of arrangement (the “Scheme”) in respect of the 5.95% notes due February 2023 and 7.25% notes due April 2023 issued by the Company (together, the “2023 Notes”), and in particular relating to the convening of a single meeting of Scheme Creditors to be held on 24 January 2023 (the “Scheme Meeting”).
  • The Company has today issued an amended Explanatory Statement in connection with the Scheme, which amends the terms of the Scheme (the “Amended Explanatory Statement”).
  • Following feedback from certain of the 2023 Noteholders, the Company has today informed the Scheme Creditors, by the Amended Explanatory Statement, that it has amended the terms of the proposal set out in the Scheme.
  • Scheme Creditors or, if a corporation, their representative, or the proxy attending the Scheme Meeting on their behalf will be required to verify their entitlement to attend the Scheme Meeting as a Scheme Creditor before they will be granted access to the Scheme Meeting by a representative of the Information Agent.

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

Retrieved on: 
Friday, September 23, 2022
Biotechnology, Pharmaceutical, Health, Stem Cells, Purchasing, Inflammation, Time, Twitter, Risk, Standstill period, Power purchase agreement, U.S. Securities and Exchange Commission, LinkedIn, Company, News, Private Securities Litigation Reform Act, Partnership, Social media, Patient, Clinical trial, Exercise, Participation, Annual report, NASDAQ, Date, SEC, Regenerative medicine, Sumathi Best Television Current Reporting Award, Security (finance), Pharmaceutical industry, Facebook

As Athersys continues to pursue licensing and other business development opportunities for our proprietary technology this amendment can help facilitate future transactions with financial and strategic investors.

Key Points: 
  • As Athersys continues to pursue licensing and other business development opportunities for our proprietary technology this amendment can help facilitate future transactions with financial and strategic investors.
  • MultiStem therapys potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.

Progressive Care Successfully Negotiates Settlement Agreement

Retrieved on: 
Monday, January 24, 2022
CVP, Research, Tobacco Master Settlement Agreement, OTCQB, GLOBE, Settlement, Standstill period, Company, Effective date, Mark (given name), Failure, Social media, Bookkeeping, Security (finance)

MIAMI, FL , Jan. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, today announced that on January 20, 2022 (the “Effective Date”), the Company reached an agreement to settle the Company’s demand (the “Company’s Demand”) on December 14, 2021 against two investors, Chicago Venture Partners, L.P. (“CVP”) and Iliad Research and Trading, L.P. (“Iliad,” and together with CVP, the “Investors”), and the response of the Investors to the Company’s Demand received on January 7, 2022 (the “Investors Demand”) as reflected in a complaint they filed against the Company (the “Settlement Agreement”). The Settlement Agreement contains customary terms and conditions and provides for the following in exchange for a mutual release of the Company and the Investors from all alleged claims.

Key Points: 
  • The Settlement Agreement contains customary terms and conditions and provides for the following in exchange for a mutual release of the Company and the Investors from all alleged claims.
  • Under the Settlement Agreement, CVP agreed to pay the Company $175,000 (CVP Payment) via wire transfer within two (2) business days of the Effective Date.
  • Upon receipt of the CVP Payment, the Securities Purchase Agreement between the Company and CVP, and all other documents entered into in connection therewith, will be deemed to be terminated and of no further force or effect.
  • For more information about Progressive Care, please visit the companys website.